{"id":520778,"date":"2021-07-30T09:10:07","date_gmt":"2021-07-30T13:10:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-bernstein-litowitz-berger-grossmann-llp-announces-investigation-of-annovis-bio-inc-and-encourages-investors-to-contact-the-firm\/"},"modified":"2021-07-30T09:10:07","modified_gmt":"2021-07-30T13:10:07","slug":"investigation-alert-bernstein-litowitz-berger-grossmann-llp-announces-investigation-of-annovis-bio-inc-and-encourages-investors-to-contact-the-firm","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-bernstein-litowitz-berger-grossmann-llp-announces-investigation-of-annovis-bio-inc-and-encourages-investors-to-contact-the-firm\/","title":{"rendered":"Investigation Alert: Bernstein Litowitz Berger & Grossmann LLP Announces Investigation of Annovis Bio, Inc. and Encourages Investors to Contact the Firm"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n NEW YORK<\/span>, July 30, 2021<\/span> \/PRNewswire\/ —\u00a0Prominent investor rights law firm Bernstein Litowitz Berger & Grossmann LLP (“BLB&G”) is investigating potential violations of the federal securities laws by Annovis Bio, Inc. (“Annovis” or the “Company”) (NYSE American: ANVS).<\/p>\n

\n

\n
\n \"Updated
\n <\/a>\n <\/p>\n<\/p><\/div>\n

BLB&G is investigating whether Annovis misled investors regarding the efficacy of its Alzheimer’s drug, Posiphen.<\/div>\n

Annovis is a clinical-stage biotechnology company developing treatments for neurodegenerative diseases.\u00a0The Company’s lead candidate is Posiphen, or ANVS401, an orally administered drug that purportedly inhibits the production of neurotoxic proteins that lead to neurodegeneration.\u00a0Annovis is currently testing Posiphen in two Phase 2 clinical trials for the treatment of Alzheimer’s Disease and Parkinson’s Disease.<\/p>\n

BLB&G’s investigation is focused on whether Annovis misled investors about Posiphen’s efficacy in treating patients with Alzheimer’s and Parkinson’s Diseases.<\/p>\n

On July 28, 2021<\/span>, after the market closed, Annovis reported clinical trial data for Posiphen that failed to show statistical significance in treating Alzheimer’s and Parkinson’s Disease patients relative to a placebo.\u00a0 On this news, Annovis’ stock price declined $65.94<\/span> per share, or over 60%.<\/p>\n

The investigation is being led by BLB&G partners Avi Josefson<\/span> and Scott R. Foglietta<\/span>.\u00a0Annovis investors who suffered a loss and would like to learn more about our investigation, please contact BLB&G at (212) 554-4444, via e-mail at inquiries@blbglaw.com<\/a>, or through the form on our website at https:\/\/www.blbglaw.com\/cases-investigations\/annovis-bio-inc<\/a>. <\/p>\n

\n
\n About BLB&G <\/u>
\n <\/b>\n <\/p>\n

BLB&G is widely recognized worldwide as a leading law firm advising institutional investors on issues related to corporate governance, shareholder rights, and securities litigation.\u00a0 Since its founding in 1983, BLB&G has built an international reputation for excellence and integrity and pioneered the use of the litigation process to achieve precedent-setting governance reforms. Unique among its peers, BLB&G has obtained several of the largest and most significant securities recoveries in history, recovering over $33 billion<\/span> on behalf of defrauded investors.\u00a0More information about the firm can be found online at www.blbglaw.com<\/a>. <\/p>\n

This press release may be considered Attorney Advertising under the applicable law and ethics rules of some jurisdictions.\u00a0Prior results do not guarantee a similar outcome.<\/p>\n

\n
\n Contact
<\/u>
\n <\/b>
\n Avi Josefson<\/span>
\n
\n Scott R. Foglietta<\/span>
\n
Bernstein Litowitz Berger & Grossmann LLP
1251 Avenue of the Americas, 44th<\/sup> Floor
New York, New York<\/span> 10020
(212) 554-4444
inquiries@blbglaw.com<\/a> \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/p>\n

<\/div>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/investigation-alert-bernstein-litowitz-berger–grossmann-llp-announces-investigation-of-annovis-bio-inc-and-encourages-investors-to-contact-the-firm-301344991.html<\/a><\/p>\n

SOURCE Bernstein Litowitz Berger & Grossmann LLP<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire NEW YORK, July 30, 2021 \/PRNewswire\/ —\u00a0Prominent investor rights law firm Bernstein Litowitz Berger & Grossmann LLP (“BLB&G”) is investigating potential violations of the federal securities laws by Annovis Bio, Inc. (“Annovis” or the “Company”) (NYSE American: ANVS). BLB&G is investigating whether Annovis misled investors regarding the efficacy of its Alzheimer’s drug, Posiphen. Annovis is a clinical-stage biotechnology company developing treatments for neurodegenerative diseases.\u00a0The Company’s lead candidate is Posiphen, or ANVS401, an orally administered drug that purportedly inhibits the production of neurotoxic proteins that lead to neurodegeneration.\u00a0Annovis is currently testing Posiphen in two Phase 2 clinical trials for the treatment of Alzheimer’s Disease and Parkinson’s Disease. BLB&G’s investigation is focused on whether Annovis misled investors about Posiphen’s efficacy … <\/p>\n

Continue reading “Investigation Alert: Bernstein Litowitz Berger & Grossmann LLP Announces Investigation of Annovis Bio, Inc. and Encourages Investors to Contact the Firm”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-520778","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nInvestigation Alert: Bernstein Litowitz Berger & Grossmann LLP Announces Investigation of Annovis Bio, Inc. and Encourages Investors to Contact the Firm - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-bernstein-litowitz-berger-grossmann-llp-announces-investigation-of-annovis-bio-inc-and-encourages-investors-to-contact-the-firm\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Investigation Alert: Bernstein Litowitz Berger & Grossmann LLP Announces Investigation of Annovis Bio, Inc. and Encourages Investors to Contact the Firm - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEW YORK, July 30, 2021 \/PRNewswire\/ —\u00a0Prominent investor rights law firm Bernstein Litowitz Berger & Grossmann LLP (“BLB&G”) is investigating potential violations of the federal securities laws by Annovis Bio, Inc. (“Annovis” or the “Company”) (NYSE American: ANVS). BLB&G is investigating whether Annovis misled investors regarding the efficacy of its Alzheimer’s drug, Posiphen. Annovis is a clinical-stage biotechnology company developing treatments for neurodegenerative diseases.\u00a0The Company’s lead candidate is Posiphen, or ANVS401, an orally administered drug that purportedly inhibits the production of neurotoxic proteins that lead to neurodegeneration.\u00a0Annovis is currently testing Posiphen in two Phase 2 clinical trials for the treatment of Alzheimer’s Disease and Parkinson’s Disease. BLB&G’s investigation is focused on whether Annovis misled investors about Posiphen’s efficacy … Continue reading "Investigation Alert: Bernstein Litowitz Berger & Grossmann LLP Announces Investigation of Annovis Bio, Inc. and Encourages Investors to Contact the Firm"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-bernstein-litowitz-berger-grossmann-llp-announces-investigation-of-annovis-bio-inc-and-encourages-investors-to-contact-the-firm\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-30T13:10:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1584940\/Bernstein_Litowitz_Berger_Grossmann_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-alert-bernstein-litowitz-berger-grossmann-llp-announces-investigation-of-annovis-bio-inc-and-encourages-investors-to-contact-the-firm\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-alert-bernstein-litowitz-berger-grossmann-llp-announces-investigation-of-annovis-bio-inc-and-encourages-investors-to-contact-the-firm\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Investigation Alert: Bernstein Litowitz Berger & Grossmann LLP Announces Investigation of Annovis Bio, Inc. and Encourages Investors to Contact the Firm\",\"datePublished\":\"2021-07-30T13:10:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-alert-bernstein-litowitz-berger-grossmann-llp-announces-investigation-of-annovis-bio-inc-and-encourages-investors-to-contact-the-firm\\\/\"},\"wordCount\":426,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-alert-bernstein-litowitz-berger-grossmann-llp-announces-investigation-of-annovis-bio-inc-and-encourages-investors-to-contact-the-firm\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1584940\\\/Bernstein_Litowitz_Berger_Grossmann_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-alert-bernstein-litowitz-berger-grossmann-llp-announces-investigation-of-annovis-bio-inc-and-encourages-investors-to-contact-the-firm\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-alert-bernstein-litowitz-berger-grossmann-llp-announces-investigation-of-annovis-bio-inc-and-encourages-investors-to-contact-the-firm\\\/\",\"name\":\"Investigation Alert: Bernstein Litowitz Berger & Grossmann LLP Announces Investigation of Annovis Bio, Inc. and Encourages Investors to Contact the Firm - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-alert-bernstein-litowitz-berger-grossmann-llp-announces-investigation-of-annovis-bio-inc-and-encourages-investors-to-contact-the-firm\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-alert-bernstein-litowitz-berger-grossmann-llp-announces-investigation-of-annovis-bio-inc-and-encourages-investors-to-contact-the-firm\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1584940\\\/Bernstein_Litowitz_Berger_Grossmann_Logo.jpg\",\"datePublished\":\"2021-07-30T13:10:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-alert-bernstein-litowitz-berger-grossmann-llp-announces-investigation-of-annovis-bio-inc-and-encourages-investors-to-contact-the-firm\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-alert-bernstein-litowitz-berger-grossmann-llp-announces-investigation-of-annovis-bio-inc-and-encourages-investors-to-contact-the-firm\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-alert-bernstein-litowitz-berger-grossmann-llp-announces-investigation-of-annovis-bio-inc-and-encourages-investors-to-contact-the-firm\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1584940\\\/Bernstein_Litowitz_Berger_Grossmann_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1584940\\\/Bernstein_Litowitz_Berger_Grossmann_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-alert-bernstein-litowitz-berger-grossmann-llp-announces-investigation-of-annovis-bio-inc-and-encourages-investors-to-contact-the-firm\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Investigation Alert: Bernstein Litowitz Berger & Grossmann LLP Announces Investigation of Annovis Bio, Inc. and Encourages Investors to Contact the Firm\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Investigation Alert: Bernstein Litowitz Berger & Grossmann LLP Announces Investigation of Annovis Bio, Inc. and Encourages Investors to Contact the Firm - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-bernstein-litowitz-berger-grossmann-llp-announces-investigation-of-annovis-bio-inc-and-encourages-investors-to-contact-the-firm\/","og_locale":"en_US","og_type":"article","og_title":"Investigation Alert: Bernstein Litowitz Berger & Grossmann LLP Announces Investigation of Annovis Bio, Inc. and Encourages Investors to Contact the Firm - Market Newsdesk","og_description":"PR Newswire NEW YORK, July 30, 2021 \/PRNewswire\/ —\u00a0Prominent investor rights law firm Bernstein Litowitz Berger & Grossmann LLP (“BLB&G”) is investigating potential violations of the federal securities laws by Annovis Bio, Inc. (“Annovis” or the “Company”) (NYSE American: ANVS). BLB&G is investigating whether Annovis misled investors regarding the efficacy of its Alzheimer’s drug, Posiphen. Annovis is a clinical-stage biotechnology company developing treatments for neurodegenerative diseases.\u00a0The Company’s lead candidate is Posiphen, or ANVS401, an orally administered drug that purportedly inhibits the production of neurotoxic proteins that lead to neurodegeneration.\u00a0Annovis is currently testing Posiphen in two Phase 2 clinical trials for the treatment of Alzheimer’s Disease and Parkinson’s Disease. BLB&G’s investigation is focused on whether Annovis misled investors about Posiphen’s efficacy … Continue reading \"Investigation Alert: Bernstein Litowitz Berger & Grossmann LLP Announces Investigation of Annovis Bio, Inc. and Encourages Investors to Contact the Firm\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-bernstein-litowitz-berger-grossmann-llp-announces-investigation-of-annovis-bio-inc-and-encourages-investors-to-contact-the-firm\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-30T13:10:07+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1584940\/Bernstein_Litowitz_Berger_Grossmann_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-bernstein-litowitz-berger-grossmann-llp-announces-investigation-of-annovis-bio-inc-and-encourages-investors-to-contact-the-firm\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-bernstein-litowitz-berger-grossmann-llp-announces-investigation-of-annovis-bio-inc-and-encourages-investors-to-contact-the-firm\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Investigation Alert: Bernstein Litowitz Berger & Grossmann LLP Announces Investigation of Annovis Bio, Inc. and Encourages Investors to Contact the Firm","datePublished":"2021-07-30T13:10:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-bernstein-litowitz-berger-grossmann-llp-announces-investigation-of-annovis-bio-inc-and-encourages-investors-to-contact-the-firm\/"},"wordCount":426,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-bernstein-litowitz-berger-grossmann-llp-announces-investigation-of-annovis-bio-inc-and-encourages-investors-to-contact-the-firm\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1584940\/Bernstein_Litowitz_Berger_Grossmann_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-bernstein-litowitz-berger-grossmann-llp-announces-investigation-of-annovis-bio-inc-and-encourages-investors-to-contact-the-firm\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-bernstein-litowitz-berger-grossmann-llp-announces-investigation-of-annovis-bio-inc-and-encourages-investors-to-contact-the-firm\/","name":"Investigation Alert: Bernstein Litowitz Berger & Grossmann LLP Announces Investigation of Annovis Bio, Inc. and Encourages Investors to Contact the Firm - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-bernstein-litowitz-berger-grossmann-llp-announces-investigation-of-annovis-bio-inc-and-encourages-investors-to-contact-the-firm\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-bernstein-litowitz-berger-grossmann-llp-announces-investigation-of-annovis-bio-inc-and-encourages-investors-to-contact-the-firm\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1584940\/Bernstein_Litowitz_Berger_Grossmann_Logo.jpg","datePublished":"2021-07-30T13:10:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-bernstein-litowitz-berger-grossmann-llp-announces-investigation-of-annovis-bio-inc-and-encourages-investors-to-contact-the-firm\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-bernstein-litowitz-berger-grossmann-llp-announces-investigation-of-annovis-bio-inc-and-encourages-investors-to-contact-the-firm\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-bernstein-litowitz-berger-grossmann-llp-announces-investigation-of-annovis-bio-inc-and-encourages-investors-to-contact-the-firm\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1584940\/Bernstein_Litowitz_Berger_Grossmann_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1584940\/Bernstein_Litowitz_Berger_Grossmann_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-bernstein-litowitz-berger-grossmann-llp-announces-investigation-of-annovis-bio-inc-and-encourages-investors-to-contact-the-firm\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Investigation Alert: Bernstein Litowitz Berger & Grossmann LLP Announces Investigation of Annovis Bio, Inc. and Encourages Investors to Contact the Firm"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/520778","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=520778"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/520778\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=520778"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=520778"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=520778"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}